Abstract: To manage accesses from a plurality of masters to a shared resource, a plurality of command registers of each holding an access command received from any of the masters and a plurality of address registers of each holding a register number identifying a command register holding a valid access command, are provided. To rearrange the issuing order of access commands, register numbers held in the address registers are rearranged.

Abstract: Bandwidth information including a plurality of slots each having highest priority order information for arbitrating access conflict, and priority master information for specifying, as a priority master, one or more of a plurality of masters whose latency in accessing a memory serving as a shared resource is desired to be reduced are included as arbitration information. When an arbitration section arbitrates access conflict while switching the slots in the bandwidth information at each of predetermined arbitration timings, if there is an access request from the priority master specified in the priority master information, the arbitration section changes the sequence of the slots in the bandwidth information so as to allow the priority master to access the memory with priority.

Abstract: This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I) or of pharmaceutically acceptable salts thereof. The crystalline forms of the 1-methylcarbapenem derivative exhibit excellent antibiotic activity against various bacterial strains and sufficient stability for practical use.

Abstract: A resource management apparatus comprises an information selection unit having an operation speed different to an operation speed of a common resource and selecting from information transferred from a plurality of bus masters, a buffer unit for storing the information selected by the information selection unit, and a timing adjustment unit for controlling timings of the information selections in the information selection unit. The information selection unit selects the information comprised of a command and data transferred from any of the plurality of bus masters to the common resource. The timing adjustment unit controls the timings of the information selections in the information selection unit so that the sum of time required for selecting a plurality of predetermined volumes of information in the information selection unit and the sum of processing time in the common resource are substantially equal to each other.

Abstract: In a multi-processor system constituted by a processor such as a CPU and a DSP, in which the processor and the DSP have an external memory and a bus as shared resources and the DSP carries out a process in response to a processing request from the processor, a monitoring step for status of use includes a step of monitoring the status of use of the DSP, and when contention information obtained in the monitoring step for the status of use indicates frequent uses, an altering step for software process appropriately alters a software processing method to be executed, and switches the corresponding process to an equivalent process so that it becomes possible to avoid bus contention, and consequently to prevent a reduction in the processing speed.

Abstract: This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I) or of pharmaceutically acceptable salts thereof.

Abstract: The states of a logic circuit block are set as operation start states and operation end states. An instruction to be analyzed is selected from input/output instruction information. An input signal corresponding to the selected instruction is applied to an RT (Register Transfer)-level model that is in the operation start state. Then, the input signal value applied to the RT-level model is changed. In order to extract operation of the logic circuit block, the RT-level model is analyzed until it reaches the operation end state. An operation model of the logic circuit block is produced based on the extracted operations. In this way, the model of the logic circuit block specifically described at RT level can be converted into a high abstraction-level model including no concept of time.

Abstract: This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I) or of pharmaceutically acceptable salts thereof.

Abstract: The invention relates to an endothelin antagonistic peptide of the formula (I): X-A-Trp-B-Gly-Thr-E-G-Y   (I) SEQ ID NO: 2 wherein represents Asn or Asp; B represents His or Lys; E represents Ala or Ser; G represents Ala or Pro; X represents X1-Gly or  and Y represents hydroxy, lower alkoxy, amino, wherein X1, X3, Y1, Y2 and Z are further defined, or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I) or of pharmaceutically acceptable salts thereof.

Abstract: Disclosed in a peptide represented by the following formula (I):

Abstract: The states of a logic circuit block are set as operation start states and operation end states. An instruction to be analyzed is selected from input/output instruction information. An input signal corresponding to the selected instruction is applied to an RT (Register Transfer)-level model that is in the operation start state. Then, the input signal value applied to the RT-level model is changed. In order to extract operation of the logic circuit block, the RT-level model is analyzed until it reaches the operation end state. An operation model of the logic circuit block is produced based on the extracted operations. In this way, the model of the logic circuit block specifically described at RT level can be converted into a high abstraction-level model including no concept of time.

Abstract: This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I) or of pharmaceutically acceptable salts thereof.

Abstract: The invention relates to biologically pure cultures of Streptomyces sp. RE-701 (FERM BP-3624) and Streptomyces sp. RE-629 (FERM BP-4126) that produce endothelin antagonistic peptides.

Abstract: A method for the prophylaxis or treatment of infectious diseases caused by helicobacter pyloir, by administering a pharmacologically effective amount of a 1-methoylcarbapenem coumpund of formula (I) or a pharmacologically acceptable salt or ester thereof: R1 represents a group of the following formula: R2 is a hydrogen atom or a C1-C6 alkyl group, and R3 is a hydrogen atom or a C1-C6 alkyl group.

Abstract: A 1-methylcarbapenem compound represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen or C.sub.1 -C.sub.4 alkyl; R.sup.2 represents hydrogen or an ester residue; and A represents a group of the formula (A1) ##STR2## wherein n is 0, 1 or 2, P is 0, 1 or 2, R.sup.3 is hydrogen or C.sub.1 -C.sub.4 alkyl and R.sup.4 is a group (Q2) ##STR3## wherein B is phenylene, phenylene(C.sub.1 -C.sub.3)alkyl, cyclohexylene, cyclohexylene(C.sub.1 -C.sub.3)alkyl or C.sub.1 -C.sub.5 alkylene, R.sup.7 is hydrogen or C.sub.1 -C.sub.4 alkyl, and R.sup.14 is a group --C(.dbd.NH)R.sup.8, wherein R.sup.8 is hydrogen or C.sub.1 -C.sub.4 alkyl or a group --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are the same or different and are hydrogen or C.sub.1 -C.sub.4 alkyl; or a pharmacologically acceptable salt thereof.

Abstract: A 1-methylcarbapenem compound represented by the following formula: ##STR1## [wherein R.sup.1 represents a hydrogen atom or a lower alkyl group, R.sup.2 represents a hydrogen atom or a lower alkyl group, R.sup.3 represents a hydrogen atom, a lower alkyl group, a lower alkyl group which has a substituent, a cycloalkyl group or a group of formula --C(.dbd.NH)R.sup.4 (in which R.sup.4 represents a hydrogen atom, a lower alkyl group or an amino group)]; or a pharmacologically acceptable salt or derivative thereof. The 1-methylcarbapenem compounds of the present invention exhibit excellent antibacterial activity and are therefore effective as a preventive or remedy of infections.

Abstract: Compound of formula (I): ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or --C(.dbd.NH)R.sup.0 where R.sup.0 is hydrogen or C.sub.1 -C.sub.6 alkyl;A is ##STR2## R.sup.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl or --C(.dbd.NH)R.sup.6 where R.sup.6 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.7 cycloalkyl; R.sup.3 and R.sup.4 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, hydroxy, carboxy, cyano, --CO.NR.sup.a R.sup.b, --OCO.NR.sup.a R.sup.b or --NR.sup.a R.sup.b, where R.sup.a and R.sup.b are independently hydrogen or C.sub.1 -C.sub.6 alkyl; R.sup.20", R.sup.21', and R.sup.22" are independently hydrogen or C.sub.1 -C.sub.6 alkyl or R.sup.20" and R.sup.21" or R.sup.20" and R.sup.22" together form a heterocyclic group; R.sup.23" and R.sup.24" are independently hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; n is 1, 2 or 3; and n.sup.3" is 1, 2 or 3.

Abstract: Compounds of formula (I): ##STR1## wherein R.sup.1x is hydrogen or methyl, R.sup.2x is hydrogen optionally substituted aliphatic hydrocarbon or acylimidoyl, R.sup.3x is hydrogen or an ester group, and Q.sup.x is cyclic or acyclic nitrogen-containing group. The compounds are potent antibiotics which are resistant to dehydropeptidase I, and are thus useful for the treatment of many microbial infections.

Abstract: Peptides represented by the following formula (I): ##STR1## wherein A represents Asn or Asp; B represents His or Lys; and E represents Ala or Ser;(1) X.sup.1 and Y.sup.1 are combined together to form a single bond as X.sup.1 --Y1, or (2) X.sup.1 represents hydrogen and Y.sup.1 represents hydroxy;and Z represents, in case of (1),Trp-Phe-Phe-Asn-Tyr-Tyr-7Hyt-Z.sup.1Trp-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-Z.sup.1,Trp-Val-Tyr-Tyr-Ala-His-Leu-Asp-Ile-Ile-Trp-Z.sup.1,Trp-Leu-Tyr-Phe-Ala-His-Gln-Asp-Val-Ile-Trp-Z.sup.1,Trp-Phe-Phe-Asn-Tyr-R-T-Z.sup.1wherein Z.sup.1 is an organic moiety,wherein R is Tyr or a covalent bond,T is Trp, Ala, Phe, Tyr, Trp-Trp, Asn-Tyr-Tyr-Trp, Trp-Asn-Tyr-Tyr-Trp, Trp-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,or in case of (2), Z representsTrp-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-Z.sup.1Trp-Val-Tyr-Tyr-Ala-His-Leu-Asp-Ile-Ile-Trp-Z.sup.1Trp-Leu-Tyr-Phe-Ala-His-Gln-Asp-Val-Ile-Trp-Z.sup.1.